PureCircle v. Sweegen — Federal Circuit Affirms on Steviol Glycoside Patents
PureCircle USA and PureCircle Sdn. Bhd. appealed to the Federal Circuit against Sweegen and Phyto Tech Corp. over three patents protecting methods for making rebaudioside X and steviol glycosides. The Federal Circuit affirmed the lower court’s ruling across all three patents in a proceeding spanning 553 days.
Federal Circuit backs PureCircle in natural sweetener patent dispute
PureCircle USA, Inc. and its Malaysian affiliate PureCircle Sdn. Bhd. — a leading producer of stevia-derived sweeteners — brought this action against Sweegen, Inc. and Phyto Tech Corp. asserting infringement of three US patents: US10023604, US10485257, and US9243273. The patents collectively cover methods for producing rebaudioside X and related steviol glycosides, compounds central to the next-generation natural sweetener market. The appeal was filed on 28 June 2022 before the Court of Appeals for the Federal Circuit in the District of Columbia circuit.
The Federal Circuit issued its ruling on 2 January 2024, ordering that the lower court decision be affirmed. The basis of termination is recorded as ‘Appeal Dismissed,’ and the court’s order states simply: ‘AFFIRMED.’ This outcome means the original trial-level findings in PureCircle’s favour survived appellate scrutiny, leaving Sweegen and Phyto Tech with no remaining avenue to challenge the infringement determination at this level. The affirmance is binding and closes this appellate chapter definitively.
A 553-day appellate duration is broadly consistent with Federal Circuit norms for multi-patent biotechnology cases, suggesting no extraordinary procedural delays or en banc complications. The brevity of the recorded verdict — a single-word ‘AFFIRMED’ — is typical of Federal Circuit affirmances issued without a published opinion, which may indicate the panel found the lower court’s reasoning clearly correct. What the public record does not reveal is whether any narrowing claim construction arguments or validity challenges accompanied the appeal, nor the precise damages or injunctive relief sustained by the affirmance.
Filing to dismissal in 553 days
553 days at the Federal Circuit — consistent with typical appellate timelines for multi-patent biotech cases
Federal Circuit affirms infringement ruling across three PureCircle patents
Affirmance locks in the original infringement finding
A Federal Circuit affirmance confirms that the trial court’s analysis — covering claim construction, infringement, and any validity defences raised — was legally sound. For PureCircle, this means the original judgment stands in full. For Sweegen and Phyto Tech, the affirmance forecloses further challenge at this level; any next step would require a petition for certiorari to the Supreme Court, a rarely granted avenue in patent disputes.
Lower ruling sustained in fullSingle-word verdict suggests affirmance without published opinion
When the Federal Circuit affirms with minimal recorded language, it typically signals a Rule 36 affirmance — a summary judgement that the lower court was correct without a new written opinion. This is procedurally significant: it means no new precedent was set and the lower court’s reasoning is the operative legal record. Practitioners should consult the district court docket for the substantive claim-by-claim findings that now carry full appellate endorsement.
Likely Rule 36 summary affirmanceThree method patents covering core steviol glycoside synthesis
The three asserted patents — US10023604, US10485257, and US9243273 — cover production methods for rebaudioside X and related steviol glycosides. Method patents in this space are strategically powerful because they cover the manufacturing process regardless of the specific commercial brand or formulation. Competitors cannot design around them simply by using a different end product name if the underlying synthesis route falls within the claimed steps.
Method claims — process-level protectionAffirmance reinforces PureCircle’s IP moat in premium stevia ingredients
Rebaudioside X is among the highest-purity, best-tasting steviol glycosides — commanding premium positioning in the natural sweetener market. An affirmed infringement finding against a direct competitor like Sweegen, which markets biosynthetic stevia alternatives, suggests PureCircle’s patent estate continues to constrain rival production routes. Other ingredient manufacturers operating in this space should treat this outcome as a signal to audit their synthesis processes against PureCircle’s claim portfolio.
Competitive IP moat reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | PureCircle USA, Inc. | Company | Stevia-derived sweetener producer — holder of US10023604, US10485257 & US9243273Search in Eureka ↗ |
| Defendant | Sweegen | Company | Sweegen Inc. and Phyto Tech Corp. — natural sweetener ingredient manufacturersSearch in Eureka ↗ |
| Plaintiff counsel | Richard T. Mulloy | Attorney | Counsel for PureCircle USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stanley Joseph Panikowski , III | Attorney | Counsel for PureCircle USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stuart Eric Pollack | Attorney | Counsel for PureCircle USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Anna G. Phillips | Attorney | Counsel for SweegenSearch in Eureka ↗ |
| Defendant counsel | Deirdre M. Wells | Attorney | Counsel for SweegenSearch in Eureka ↗ |
| Defendant counsel | Dennies Varughese | Attorney | Counsel for SweegenSearch in Eureka ↗ |
| Defendant counsel | John Christopher Rozendaal | Attorney | Counsel for SweegenSearch in Eureka ↗ |
| Defendant counsel | Michael E. Joffre | Attorney | Counsel for SweegenSearch in Eureka ↗ |
| Defendant counsel | Sasha Rao | Attorney | Counsel for SweegenSearch in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Court of Appeals for the Federal Circuit — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The Federal Circuit’s order — ‘AFFIRMED’ — is terse by design, consistent with a Rule 36 summary affirmance that endorses the lower tribunal’s reasoning without issuing new written guidance. For PureCircle, this closes the appellate record in their favour, leaving the original infringement finding and any associated relief fully intact. For Sweegen and Phyto Tech, no further appellate avenue exists at this level short of a certiorari petition, which is rarely granted in patent cases absent a circuit split or constitutional question.
US10023604, US10485257 & US9243273 — Steviol Glycoside Synthesis Methods
The three patents at the centre of this dispute — US10023604 (application US14/873476), US10485257 (application US15/400325), and US9243273 (application US14/469076) — collectively protect process-level innovations for producing steviol glycosides, with particular emphasis on rebaudioside X. Steviol glycosides are the bioactive compounds derived from the Stevia rebaudiana plant that deliver sweetness without caloric contribution. Rebaudioside X is a minor glycoside prized for its clean taste profile and is increasingly targeted for use in premium food and beverage reformulation. The sequential application numbers suggest a family of related inventions developed over a multi-year period, consistent with PureCircle’s strategy of building layered protection around its core synthesis platform.
Method patents in the steviol glycoside space carry particular strategic weight because they protect the how of production, not merely the what. A competitor cannot circumvent these claims simply by marketing under a different brand name if the underlying enzymatic, fermentation, or extraction process falls within the claimed steps. PureCircle — as one of the world’s largest stevia ingredient suppliers — has consistently used its patent portfolio to differentiate its biosynthetic and plant-derived production capabilities from lower-cost competitors. This case, sustained at the Federal Circuit level, signals that the barrier to entry around Reb X production methods remains high and legally enforceable.
Should your team run an FTO against US10023604, US10485257 & US9243273?
Any R&D team or ingredient manufacturer working with rebaudioside X, rebaudioside M, or related high-purity steviol glycosides should treat these three patents as active risks requiring formal freedom-to-operate analysis. The Federal Circuit’s affirmance confirms they carry enforceable claim scope. This applies equally to companies using enzymatic conversion, microbial fermentation, or semi-synthetic routes — all common approaches in the biosynthetic stevia sector — not only those attempting to replicate PureCircle’s exact process.
PatSnap Eureka’s FTO Search Agent can map your specific synthesis steps against the independent and dependent claims of all three patents simultaneously, flagging overlap risk and identifying prior art that may support design-around arguments. For ongoing monitoring, Eureka’s claim alert system will notify you if PureCircle files continuation applications that extend coverage to adjacent glycoside compounds or modified process steps — ensuring your product pipeline stays ahead of the patent landscape rather than reacting to litigation.
Run a freedom-to-operate analysis on US10023604 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patent appeals in the natural ingredients and biotech space
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the stevia and natural sweetener IP landscape
A Federal Circuit affirmance on method patents covering rebaudioside X has direct implications for every competitor operating in the biosynthetic sweetener space.
Method patents on glycoside synthesis are surviving appellate scrutiny
PureCircle’s three method patents withstood both trial and Federal Circuit review. For ingredient manufacturers and food-tech R&D teams, this confirms that process-level IP in steviol glycoside synthesis carries enforceable weight. Any production route touching rebaudioside X or related glycosides warrants a formal FTO assessment before scale-up.
Sweegen’s multi-patent challenge failed — portfolio breadth matters
Challenging three related patents simultaneously is resource-intensive and rarely succeeds if the patents share well-drafted priority chains. The affirmance across all three patents in a single proceeding suggests PureCircle’s portfolio architecture is robust. Competitors should evaluate whether design-around options exist at the biosynthetic pathway level, not merely at the compound level.
PureCircle v Sweegen — key questions answered
The Federal Circuit affirmed the lower court’s ruling in favour of PureCircle. Case No. 22-1946, filed 28 June 2022 and closed 2 January 2024, ended with a single-word order — ‘AFFIRMED’ — sustaining the infringement finding across all three asserted patents covering steviol glycoside and rebaudioside X production methods.
PureCircle asserted three US patents: US10023604 (application US14/873476), US10485257 (application US15/400325), and US9243273 (application US14/469076). All three cover method claims relating to the production of rebaudioside X and steviol glycosides — compounds used in natural, zero-calorie sweetener applications.
An affirmance at the Federal Circuit confirms the trial-level infringement finding stands. Sweegen and Phyto Tech have no further appellate avenue at this level. Their only remaining option would be a petition for certiorari to the US Supreme Court, which is rarely granted in patent cases absent a circuit split or significant constitutional issue.
Rebaudioside X (Reb X) is a minor steviol glycoside found in the stevia plant, valued for its exceptionally clean, sugar-like taste profile. It is increasingly used in premium food and beverage reformulation as manufacturers seek to reduce sugar without off-notes. Patent control over Reb X production methods — as PureCircle holds — creates a significant barrier to entry for competing ingredient suppliers.
The public record reflects only a terse ‘AFFIRMED’ order with no extended reasoning reproduced in the available case data. This is consistent with a Rule 36 summary affirmance, in which the Federal Circuit signals agreement with the lower court’s reasoning without issuing a new written opinion. Practitioners should consult the underlying district court record for substantive claim construction and infringement analysis.
PatSnap Eureka searches patents and litigation data to answer instantly.